{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
methyl salicylate
to a specific field?
Class (Stereo):
CHEMICAL (RACEMIC)
Diniprofylline is a vasodilator, broncholytic agent and respiratory stimulant used in severe respiratory insufficiencies.
Status:
Investigational
Source:
NCT01452373: Phase 3 Interventional Completed Vasomotor Symptoms
(2011)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
Acolbifene, the active metabolite of EM-800, was identified as a pure antagonist that acts on both activation domains of the ERs. It is in Phase III clinical trials for the prevention of breast cancer and vasomotor symptoms (Hot flush) in postmenopausal women. Most commonly reported adverse events included irregular menses, leg/muscle cramps, diarrhea, and hot flashes. No serious adverse events were reported.
Status:
Investigational
Source:
NCT03109886: Phase 2 Interventional Completed Hepatocellular Carcinoma
(2017)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
An orally bioavailable inhibitor of cyclin-dependent kinases (CDKs) and thropomyosin receptor kinase A (TRKA), with potential antineoplastic activity. CDK2/TRKA inhibitor PHA-848125 AC potently inhibits cyclin-dependent kinase 2 (CDK2) and exhibits activity against other CDKs including CDK1 and CDK4, in addition to TRKA. Inhibition of these kinases may result in cell cycle arrest and apoptosis of tumor cells that express these kinases. Milciclib is currently in phase II clinical trials for thymic carcinoma, glioma and liver cancer. The most common adverse events are nausea and asthenia, vomiting, myasthenic syndrome, dehydration, hypophosphatemia, cytolytic hepatitis and plantar fasciitis.
Status:
Investigational
Source:
NCT00458159: Phase 1 Interventional Terminated Myelodysplastic Syndrome
(2007)
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Class (Stereo):
CHEMICAL (MIXED)
FENETRADIL is a coronary dilator.
Status:
Investigational
Class (Stereo):
CHEMICAL (ACHIRAL)
Ditolamide is uricosuric drugs developed for the control of hyperuricemia in patients with gout.
Status:
Investigational
Source:
INN:levoprotiline [INN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT00426816: Phase 2 Interventional Completed Sleep Initiation and Maintenance Disorders
(2006)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT00460278: Phase 1 Interventional Suspended Cancer
(2007)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
XL418 is a dual protein kinase B (Akt) and ribosomal protein S6 Kinase (p70 S6K) inhibitor that also acts as an ATP-pocket binder with potential antineoplastic activity. XL418 was involved in phase I clinical trial in patients with solid tumors, however, in Dec 2007, this study was discontinued, due to low drug exposure.
Class (Stereo):
CHEMICAL (UNKNOWN)
Crufomate is an insecticide and antihelmintic drug which acts by inhibition of acetylcholinesterase. Crufomate was used on or in cattle, sheep, and goats to control internal cattle grubs and external horn flies and cattle lice. Crufomate is administered by injection, oral administration, and spraying. For the treatment of internal helminth parasites, crufomate is administered by the oral drench directly into the rumen.
